Ulipristal Acetate for Use in Moderate to Severe Symptoms of Uterine Fibroids | Zendy

Vikram Talaulikar | Zendy; Isaac Manyonda | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ulipristal Acetate for Use in Moderate to Severe Symptoms of Uterine Fibroids

Author(s) -

Vikram Talaulikar,

Isaac Manyonda

Publication year - 2014

Publication title -

women s health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.363

H-Index - 39

eISSN - 1745-5065

pISSN - 1745-5057

DOI - 10.2217/whe.14.60

Subject(s) - ulipristal acetate , uterine fibroids , medicine , gynecology , research methodology , family planning , population , environmental health

Although it has been known for a long time that uterine fibroids respond to changes in sex steroid concentrations, it is the availability of selective progesterone receptor modulators such as ulipristal acetete that has provided the gynecologist with a novel option for medical management of uterine fibroids. Ulipristal acetate is presently licensed in Europe for use in women with symptomatic fibroids up to 3 months prior to surgery and has demonstrated good clinical efficacy and safety for this indication. Future trials will define the long-term safety of this drug and its role in medical management of uterine fibroids.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research